Design, preparation and in vitro characterizations of fluconazole loaded nanostructured lipid carriers

Fernandes, Amanda Velinna; Pydi, Chinna Raja; Verma, Ruchi; Jose, Jobin; Kumar, Lalit

doi:10.1590/s2175-97902019000318069

Cited by 38 publications

(18 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PDI less than 0.3 is considered very homogenous populations of SLN. Based on Table I, the prepared SLNs had a PDI value of ≤ 0.5, which can be acceptable (25)(26)(27)(28)(29)(30). The particle size distribution of the optimized formulation and some of the solid lipid nanoparticle formulations are shown in supplementary materials (Fig.…”

Section: Effect Of Hlb Of Surfactants On Nanoparticles Propertiesmentioning

confidence: 97%

Atorvastatin Solid Lipid Nanoparticles as a Promising Approach for Dermal Delivery and an Anti-inflammatory Agent

et al. 2020

View full text Add to dashboard Cite

In the current research, the main focus was to overcome dermal delivery problems of atorvastatin. To this end, atorvastatin solid lipid nanoparticles (ATR-SLNs) were prepared by ultra-sonication technique. The prepared SLNs had a PDI value of ≤ 0.5, and the particle size of nanoparticles was in the range 71.07 ± 1.72 to 202.07 ± 8.40 nm. It was noticed that, when the concentration of lipid in ATR-SLNs increased, the size of nanoparticles and drug entrapment efficiency were also increased. Results showed that a reduction in the HLB of surfactants used in the preparation of SLN caused an increase in the particle size, zeta potential (better stability), and drug entrapment efficiency. Despite Tween and Span are non-ionic surfactants, SLNs containing these surfactants showed a negative zeta potential, and the absolute zeta potential increased when the concentration of Span 80 was at maximum. DSC thermograms, FTIR spectra, and x-ray diffraction (PXRD) pattern showed good incorporation of ATR in the nanoparticles without any chemical interaction. In vitro skin permeation results showed that SLN containing atorvastatin was capable of enhancing the dermal delivery of atorvastatin where a higher concentration of atorvastatin can be detected in skin layers. This is a hopeful promise which could be developed for clinical studies of the dermal delivery of atorvastatin nanoparticles as an anti-inflammatory agent.

show abstract

Section: Effect Of Hlb Of Surfactants On Nanoparticles Propertiesmentioning

confidence: 97%

Atorvastatin Solid Lipid Nanoparticles as a Promising Approach for Dermal Delivery and an Anti-inflammatory Agent

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The PDI of co-Q10 NLCs (F6), (F7), and (F8) were<0.5, as shown in table 5. This indicates that the particle size distribution of the co-Q10 NLCs (F6), (F7), and (F8) were homogenous [21,22].…”

Section: Physicochemical Characterization Of the Co-q10 Nlcsmentioning

confidence: 87%

EXPERIMENTAL DEVELOPMENT AND MOLECULAR DOCKING: NANOSTRUCTURED LIPID CARRIERS (NLCs) OF COENZYME Q10 USING STEARIC ACID AND DIFFERENT LIQUID LIPIDS AS LIPID MATRIX

Aryani¹,

Siswandono²,

Soeratri³

et al. 2021

Int J App Pharm

View full text Add to dashboard Cite

Objective: To develop coenzyme Q10 (co-Q10) nanostructured lipid carriers (NLCs) using stearic acid (SA) and various liquid lipids with different lipophilicity as well as highlights the use of in silico studies for predicting and elucidating the interaction of drug-lipid used as carries in NLCs, at the molecular level. Methods: The co-Q10 NLCs were prepared using SA as solid lipid and oleic acid (OA), isopropyl myristate (IPM), as well as isopropyl palmitate (IPP) as liquid lipids by the high shear homogenization method. Firstly, the formulas were optimized by the appropriate required HLB (rHLB). The optimized NLCs were characterized in the particle size, distribution of particle size, zeta potential, crystallinity behavior, Fourier transform infrared (FT-IR) spectra, morphology, entrapment efficiency (EE), drug loading (DL), and pH value. The interaction of drug-lipids in silico was studied using the AutoDock Vina program. Results: The co-Q10 NLCs using SA and the various liquid lipid possessed the mean particle size, polydispersity index (PDI), zeta potential, EE, DL, and pH values were 180 to 350 nm,<0.5,<-30 mV, 83 to 88%, 10 to 11%, and 5.0 to 5.6, respectively. The EE and DL of co-Q10 NLCs increased with decreasing in binding energy (∆G) in silico. Conclusion: The co-Q10 NLCs using SA as solid lipid and OA, IPM, as well as IPP as liquid lipids were developed successfully. Furthermore, in silico study by molecular docking is a potential approach in predicting and elucidating the interaction of drug-lipid in the development of NLCs formulation.

show abstract

“…Filtrate was collected and analysed in triplicate using developed HPLC method. The percent entrapment efficiency of LTG loaded lipid nanoformulation was calculated using the below given formula [24]:…”

Section: Application Of Developed Hplc Methods For Estimation Of Lamotmentioning

confidence: 99%

Analytical Method Development Using Central Composite Design for Estimation of Lamotrigine in Lipid Nanoformulation

Gangurde¹,

Bhaskaran²,

Verma³

et al. 2020

Mater. Plast.

Self Cite

View full text Add to dashboard Cite

Objective of this study was to develop and validate HPLC-UV method for detection of LTG in lipid nanoformulations. HPLC-UV method was developed according to ICH Q2(R1) guidelines. Central composite design was used effectively to optimize and study the effect of buffer strength, flow rate, pH of buffer and mobile phase composition on responses such as tailing factor, peak area, retention time and number of theoretical plates. The 30 mM ammonium formate buffer and acetonitrile (in the ratio 65:35 %v/v) was used as mobile phase in the study. The mobile phase was delivered at the flow rate of 1.0 mL/min. The detection of buffer was performed at 256 nm using UV detector. The drug entrapment of prepared formulation was also determined using developed HPLC method. Retention time of lamotrigine was found to be 3.844 min. The coefficient of determination (r2) value from linearity was found to be 0.9982. Percent relative standard deviation value of precision was found to be within the acceptable range. The estimated LOD and LOQ were found to be 9.07 ng/mL and 27.48 ng/mL, respectively. Drug entrapment of prepared lipid nanoformulation was found to be 73.44 � 6.65%. The results conclude that the developed analytical method is simple, precise, sensitive, fast and reproducible. Applications of developed method for determination of drug entrapment in prepared lipid nanoformulation confirmed that the developed analytical method is suitable for estimation of lamotrigine in lipid nanoformulations.

show abstract

Design, preparation and in vitro characterizations of fluconazole loaded nanostructured lipid carriers

Cited by 38 publications

References 47 publications

Atorvastatin Solid Lipid Nanoparticles as a Promising Approach for Dermal Delivery and an Anti-inflammatory Agent

Atorvastatin Solid Lipid Nanoparticles as a Promising Approach for Dermal Delivery and an Anti-inflammatory Agent

EXPERIMENTAL DEVELOPMENT AND MOLECULAR DOCKING: NANOSTRUCTURED LIPID CARRIERS (NLCs) OF COENZYME Q10 USING STEARIC ACID AND DIFFERENT LIQUID LIPIDS AS LIPID MATRIX

Analytical Method Development Using Central Composite Design for Estimation of Lamotrigine in Lipid Nanoformulation

Contact Info

Product

Resources

About